Overview
Global Business Reports quoted Steptoe New York partner Vishal Gupta in an article titled “Navigating the Regulatory Framework: Balancing Regulations, Safeguards and Incentives.” The article, published in the 2017 United States Pharmaceuticals Industry Explorations issue, discusses how – even within the boundaries of the Hatch-Waxman framework – the IP industry has seen an increasing trend for post-grant proceedings, such as post-grant review (PGR) and inter partes review (IPR) processes at the patent office. By making minor changes to a product and pursuing new patents, brand companies prohibit their generic-producing competitors from market entry.
Mr. Gupta says: “Specifically, with respect to pharmaceutical IPRs, when it comes to formulation and compound patents, it has been observed that compound patents tend to be invalidated less than formulations patents. Looking forward, in addition to IPRs we will see the PGR area grow in the life sciences space.”
The full article can be read at Global Business Reports.
